Xsolla Expands Mobile and Digital Distribution Solution Offerings and Adds an NFT Checkout to the Growing Set of Tools and Services for Developers
28.4.2022 11:06:00 EEST | Business Wire | Press release
Xsolla, a global video game commerce company, announced today that it has expanded their mobile and digital distribution solutions to provide more opportunities for developers to launch and grow their games around the world. In addition, Xsolla has added a new checkout feature to help developers scale their brands by selling and distributing NFTs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220428005554/en/
XSOLLA EXPANDS MOBILE AND DIGITAL DISTRIBUTION SOLUTION OFFERINGS AND ADDS AN NFT CHECKOUT TO THE GROWING SET OF TOOLS AND SERVICES FOR DEVELOPERS (Graphic: Business Wire)
“Xsolla is committed to providing best-in-class services and support for developers worldwide to help them reach more players in more geographies,” stated Chris Hewish, President of Xsolla. “We continue to develop new features that target the key challenges of marketing, launching, and monetizing video games. We have more to come in 2022 that will keep our partners ahead of the constantly evolving game climate.”
Mobile Web Shop - New Features
As the expanding mobile landscape continues to lead global gaming revenue, Xsolla’s Web Shop for Mobile Games has added new features to help mobile developers to reach more players and to remain at the forefront of the mobile gaming revolution.
● Expanded Analytics
Developers can create a transparent funnel that will increase efficiency in bringing new players to their Web Shop. This will help developers understand the player experience online and determine where and how users engage with their game.
● Unique Promotions
This built-in component helps developers benefit from in-app purchases through their Web Shop. Within the online experience, developers can provide promotional offers and launch discount campaigns, promo code offers, and bonuses to boost sales and bring new players online.
● Subscriptions Management
To help developers sell a complete catalog of digital goods in their Web Shop, Xsolla added robust subscription features. This allows developers to gain and retain new customers, create loyalty, generate reliable revenue streams, and manage subscriptions with confidence.
For more information about the Xsolla Web Shop, visit: https://xsolla.com/solution/web-shop-for-mobile-games
NFT Checkout
Xsolla has created an NFT Checkout process to allow developers to quickly and securely add NFTs to their game economy. This feature enables players to make purchases using their preferred payment method. The developer handles the minting and the delivery of the NFTs, while Xsolla handles the checkout and in-game items distribution process.
For more details about NFT Checkout, visit: https://xsolla.com/solution/payments/nft-checkout
Digital Distribution Hub
Xsolla Digital Distribution Hub connects games to a global network of apps, internet service providers (ISPs), banks, and other channels to help developers reach players and gain revenue from every transaction. This new solution empowers gamers to discover and support their favorite games through an optimized multi-platform experience and allows them to pay how and when they want.
Developers can now benefit from increased market penetration and brand awareness through distribution channels, such as super apps, online banking apps and mobile carrier marketplaces. With the Digital Distribution Hub your game can reach a vast audience of new users, save on distribution costs, and boost overall revenue and engagement.
To learn more about Digital Distribution Hub, visit: https://xsolla.com/products/digital-distribution-hub
Xsolla will present these solutions and more at several upcoming events, including GamesBeat Summit 2022, Pocket Gamer Connects Seattle, Nordic Game Show, Pocket Gamer Toronto, China Joy, and gamescom, in the next six months. Register to meet up with the experts at Xsolla by visiting: https://xsolla.com/events.
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the video game industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in Berlin, Seoul, and cities around the world, Xsolla supports major gaming titles like Valve, Twitch, Roblox, Ubisoft, Epic Games, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.
For additional information and to learn more, please visit: xsolla.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220428005554/en/
Contact information
Derrick Stembridge
Director of Public Relations, Xsolla
d.stembridge@xsolla.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom